98%
921
2 minutes
20
Background: Blood products are a lifesaving but limited resource, particularly in resource-limited settings. Evidence-based transfusion criteria tailored to local hospitals have shown great promise in reducing costs, minimising shortages, and ameliorating the morbidity and mortality associated with liberal blood product usage. We implemented the "Saving Blood, Saving Lives" project to: promote responsible blood product use and reduce blood product ordering inefficiencies and expenditure.
Methods: A comprehensive change management programme, preceded by 3 months of clinical department consultation and training, was implemented. A new evidence-based protocol for blood product utilisation was developed, together with an accountability form. This form was used in monthly audit meetings to refine policies, identify new problems, improve communication, and to drive hospital staff accountability and training. The primary measure of the programme's success was the change in the number of red cell concentrate units ordered.
Results: Project implementation required minimal time and no additional budget or staff. Annual red cell concentrate usage reduced from 7211 units in year one to 4077 units in year 5 (p < 0.001). Similar reductions were seen in freeze-dried plasma and platelet usage, as well as administrative costs. Total project saving, adjusted to baseline admission numbers, amounted to over R46 million ($2.5 million).
Conclusions: As a change management programme centred the "Saving Blood, Saving Lives" project, was able to significantly reduce blood product-related administration and expenditure by implementing evidence-based transfusion criteria. The programme is simple, replicable and cost effective, making it ideally suited for use in resource-constrained environments.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/tme.13025 | DOI Listing |
J Neurooncol
September 2025
Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Purpose: Glioblastoma (GBM) remains one of the most aggressive primary brain tumors with poor survival outcomes and a lack of approved therapies. A promising novel approach for GBM is the application of photodynamic therapy (PDT), a localized, light-activated treatment using tumor-selective photosensitizers. This narrative review describes the mechanisms, delivery systems, photosensitizers, and available evidence regarding the potential of PDT as a novel therapeutic approach for GBM.
View Article and Find Full Text PDFVet Res Commun
September 2025
Department of Animal Industry Convergence, Kangwon National University, Chuncheon, 24341, Republic of Korea.
Global warming causes heat stress in livestock, impairing their health, welfare, and productivity. In bovines, chronic stress elevates cortisol levels; however, this response often goes undetected due to the lack of practical biomatrices for accurate assessment. Common biomatrices such as blood require repeated sampling that may affect measurement accuracy.
View Article and Find Full Text PDFAmino Acids
September 2025
Colorectal Research Center, Iran University of Medical Sciences, Tehran, 1445613131, Iran.
Anal fissure causes pain and bleeding during or after bowel movements, significantly impacting individuals' quality of life. Current treatments aim to interrupt this cycle but have associated risks and limitations. The emergence of arginine, crucial for protein creation and nitric oxide (NO) production, presents an intriguing therapeutic avenue by the impact on reducing anal sphincter pressure and enhancing anoderm blood flow, due to its roles in vasodilation, anti-inflammatory responses, and collagen synthesis, which can promote wound healing and highlighting its potential as an alternative therapy.
View Article and Find Full Text PDFAnn Hematol
September 2025
Excellence Center for Comprehensive Cancer (ECCCC), King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Despite therapeutic advances, multiple myeloma (MM) remains incurable, especially in relapsed/refractory (R/R) cases. B-cell maturation antigen (BCMA) is a key target for novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific T-cell engagers (BiTEs), which vary in efficacy, toxicity, and accessibility. To compare the efficacy and safety of BCMA-directed CAR-T therapies and BiTEs in R/R MM through a systematic review and meta-analysis.
View Article and Find Full Text PDFAnn Hematol
September 2025
Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
To evaluate whether age modifies the association between the geriatric nutritional risk index (GNRI) and overall survival (OS) in patients aged ≥ 18 years with newly diagnosed diffuse large B-cell lymphoma (DLBCL), we conducted a multi-centre retrospective study of 552 patients. Multivariable Cox regression with restricted cubic spline (RCS) modelling showed that GNRI was significantly associated with OS, but the relationship was non-linear (P for non-linearity = 0.0158).
View Article and Find Full Text PDF